Guides / Research peptides

Peptide half-life chart

Half-life is how long it takes for half a dose to leave your blood. Every figure below names its source and says whether it was measured in people or only in animals.

By PeptideTracker editorial team · Updated November 8, 2026 · 18 sources

[00] Short answer

  1. From the US labels: semaglutide about 1 week, tirzepatide about 5 days, dulaglutide about 5 days, liraglutide about 13 hours.
  2. After 5 half-lives, about 3.1% of a dose is left. For semaglutide that's about 5 weeks, which matches the Ozempic label.
  3. From human studies: CJC-1295 with DAC 5.8 to 8.1 days, ipamorelin about 2 hours, tesamorelin 8 to 11 minutes.
  4. BPC-157 and TB-500 have no measured half-life in people. BPC-157 lasted about 15 minutes in rats.

What does half-life mean for a peptide?

A peptide's half-life is the time it takes for the amount in your blood to fall by half. If semaglutide's half-life is about 1 week, then a week after a dose about half is left, and after another week about a quarter1.

Half-life is an average from a study group. Labels give a typical figure, and yours may be a little shorter or longer. It also only describes how fast a peptide leaves the blood. That isn't always the same as how long its effects last, which is covered further down.

Peptide half-life chart (humans vs animals)

Most peptides in the chart were measured in people. BPC-157 and TB-500 have animal figures only, and CJC-1295 without DAC has none. The GLP-1 figures come from section 12.3 of each US prescribing information. Research peptides are listed only where a published study gives a number.

Peptide half-lives, with where each figure was measured and its source
PeptideHalf-lifeMeasured inSource
Semaglutide (Ozempic, Wegovy)about 1 weekHumansUS prescribing information, 12.31–2
Tirzepatide (Mounjaro, Zepbound)about 5 days (5 to 6 days in people with overweight or obesity)HumansUS prescribing information, 12.33–4
Dulaglutide (Trulicity)about 5 daysHumansUS prescribing information, 12.35
Liraglutide (Victoza, Saxenda)about 13 hoursHumansUS prescribing information, 12.36–7
Natural GLP-1 (made by the body)1.5 to 2 minutesHumansVictoza prescribing information, 12.16
Retatrutide (LY3437943)about 6 daysHumans (phase 1b trial, type 2 diabetes)Urva 2022, Lancet8
Tesamorelin (Egrifta SV, Egrifta WR)8 minutes (Egrifta SV), 11 minutes (Egrifta WR)Humans (healthy adults, one dose under the skin)US prescribing information, 12.39–10
Sermorelin (GHRH 1-29)4.3 minutes by IV drip; a review gives about 10 to 20 minutesHumans (10 healthy men)Soule 1994; Esposito 200311–12
CJC-1295 with DAC5.8 to 8.1 daysHumans (healthy adults, under the skin)Teichman 200613
CJC-1295 without DAC (mod GRF 1-29)Not establishedNo published human figure foundNone found on PubMed (November 2026)
Ipamorelinabout 2 hoursHumans (healthy men, IV drip)Gobburu 199915
BPC-157Not established in humans. 15.2 minutes in rats, 5.3 minutes in dogs (IV)Animals onlyHe 2022; FDA 2026 review16–17
TB-500Not established. In horses, too low to measure 6 to 10 hours after 10 mgAnimals onlyFDA 2026 review18

How long does a peptide stay in your system? The 5 half-lives rule

About 5 half-lives. By then about 3.1% of a dose is left, which is the usual point for calling a peptide mostly out of your system. Each half-life removes half of what remains, so the amount drops fast at first and then more slowly.

How much of one dose is left after each half-life
Time passedLeft in the bodyCleared
1 half-life50%50%
2 half-lives25%75%
3 half-lives12.5%87.5%
4 half-lives6.3%93.8%
5 half-lives3.1%96.9%

The labels agree with this rule. The Ozempic label says that with a half-life of about 1 week, semaglutide stays in the circulation for about 5 weeks after the last dose1. The Wegovy label says about 5 to 7 weeks after the last injection of 2.4 mg or 7.2 mg2. It also says to stop Wegovy at least 2 months before a planned pregnancy because of semaglutide's long half-life2.

Label half-life and roughly when 5 half-lives have passed after the last dose
MedicineHalf-life5 half-lives
Semaglutide (Ozempic, Wegovy)about 1 week1–2about 5 weeks
Tirzepatide (Mounjaro, Zepbound)about 5 days3–4about 25 days
Dulaglutide (Trulicity)about 5 days5about 25 days
Liraglutide (Victoza, Saxenda)about 13 hours6–7about 3 days
[Tool]Count from your last doseSee roughly how much is left on any date, using the label half-life

This is about how much is left in your blood. It isn't the same as how long a drug shows up on a test, and it doesn't tell you when it's fine to start something else. Ask your prescriber or pharmacist about timing.

Why do some peptides last minutes and others a week?

Mostly, it's how well a peptide is protected from being broken down and cleared. Natural GLP-1 lasts only 1.5 to 2 minutes because enzymes in the body break it down fast6. The longer-acting GLP-1 medicines are built to avoid that. Some of them stick to albumin, a protein in your blood, which slows how fast they are broken down and filtered out:

  • Semaglutide: albumin binding is the main reason its half-life is long, and it is also protected from the enzyme DPP-41.
  • Tirzepatide: a fatty acid chain lets it bind albumin and makes the half-life longer3.
  • Liraglutide: it resists the same enzymes, and its molecules cluster together under the skin, which slows absorption. That gives about 13 hours, suited to once-daily use6.
  • CJC-1295 with DAC: it carries a chemical group that attaches it to albumin in the blood. In rats it was still in the blood after 72 hours14, and in people its half-life was 5.8 to 8.1 days13.

Peptides without that kind of protection clear in minutes. Tesamorelin's half-life is 8 to 11 minutes9–10, and sermorelin cleared in about 4 minutes during an IV drip11. BPC-157 holds up in gastric juice in a test tube, but in animals it is gone from the blood in minutes, which FDA's reviewers put down to enzymes in the blood and tissues17.

Why does the same peptide have more than one half-life?

The number can change with the product, the route, the dose and who was studied. Tesamorelin is a clear example. Its half-life was 8 minutes for Egrifta SV and 11 minutes for Egrifta WR, each measured in healthy adults after one dose under the skin9–10.

  • Who was studied. The Mounjaro label gives tirzepatide about 5 days. The Zepbound label gives about 5 to 6 days in people with overweight or obesity3–4.
  • Route and dose. In rats, BPC-157's half-life was 15.2 minutes after an IV dose, but 7.9 to 29.7 minutes after injection into muscle, rising with the dose16.
  • How it was measured. The sermorelin figure of 4.3 minutes comes from a steady IV drip11. A review gives a wider range of about 10 to 20 minutes in humans12.

So the chart names where each figure came from, and shows both when two sources differ.

Is half-life the same as how long a peptide works?

No. Half-life is how fast a peptide leaves the blood, and its effects can be shorter or longer than that. Growth hormone peptides are a good example.

  • Ipamorelin has a half-life of about 2 hours. In the same study, the growth hormone it released peaked at about 40 minutes (0.67 hours) and then fell away15.
  • CJC-1295 with DAC has a half-life of 5.8 to 8.1 days. After one injection, growth hormone stayed raised for 6 days or more and IGF-1 for 9 to 11 days. After several doses, IGF-1 stayed above baseline for up to 28 days13.

For the licensed medicines, the label is the place to check how the dose schedule was set.

What is the half-life of BPC-157 and TB-500?

No one has published a human half-life for either. FDA reviewed both in 2026. It found no human data on how BPC-157 moves through the body (pharmacokinetics) by mouth, injection under the skin, nose or skin, and no human studies of TB-500 at all17–18.

BPC-157 in animals: a 2022 study measured a half-life of 15.2 minutes in rats and 5.3 minutes in dogs after an IV dose. After injection into muscle it was under 30 minutes in both species16.

TB-500 in animals: no half-life has been published. In horses given 10 mg under the skin, blood levels peaked 1 to 2 hours later and were too low to measure by 6 to 10 hours18. That study was designed to build a doping test, not to measure half-life.

Any human half-life for these peptides that you see online is an estimate, not a measurement. For more on how the two compare, see BPC-157 vs TB-500.

Questions

What is the half-life of semaglutide?

About 1 week, according to the Ozempic and Wegovy US prescribing information. The Ozempic label says semaglutide stays in the circulation for about 5 weeks after the last dose.

What is the half-life of tirzepatide?

About 5 days, according to the Mounjaro label. The Zepbound label gives about 5 to 6 days in people with overweight or obesity. Five half-lives is roughly 25 days.

What is the half-life of BPC-157?

BPC-157's half-life in humans is not known. In a 2022 animal study it was 15.2 minutes in rats and 5.3 minutes in dogs after an IV dose, and under 30 minutes after an injection into muscle.

What is the half-life of CJC-1295 with DAC?

5.8 to 8.1 days in healthy adults, from a 2006 study in the Journal of Clinical Endocrinology and Metabolism. No published human figure was found for CJC-1295 without DAC.

What is the half-life of ipamorelin?

About 2 hours, from a 1999 study in healthy men who were given ipamorelin by IV drip.

Why five half-lives?

Because after 5, only about 3% of a dose remains, which is the usual rule of thumb for mostly cleared. Each half-life removes half of what's left.

Sources

Checked against the US prescribing information for Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda and Egrifta (DailyMed), published trials on PubMed, and FDA's July 2026 BPC-157 and TB-500 reviews. How we check

  1. 1Ozempic (semaglutide) injection US prescribing information (DailyMed). sections 12.1 and 12.3
  2. 2Wegovy (semaglutide) US prescribing information (DailyMed). sections 8.3 and 12.3
  3. 3Mounjaro (tirzepatide) US prescribing information (DailyMed). sections 12.1 and 12.3
  4. 4Zepbound (tirzepatide) US prescribing information (DailyMed). section 12.3
  5. 5Trulicity (dulaglutide) US prescribing information (DailyMed). section 12.3
  6. 6Victoza (liraglutide) US prescribing information (DailyMed). sections 12.1 and 12.3
  7. 7Saxenda (liraglutide) US prescribing information (DailyMed). section 12.3
  8. 8Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869-81
  9. 9Egrifta SV (tesamorelin) US prescribing information (DailyMed). section 12.3
  10. 10Egrifta WR (tesamorelin) US prescribing information (DailyMed). section 12.3
  11. 11Soule S et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994;79(4):1208-11
  12. 12Esposito P et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279-91. sermorelin is GRF 1-29; half-life in humans
  13. 13Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805
  14. 14Jetté L et al. hGRF1-29-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8
  15. 15Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6
  16. 16He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. half-life tables
  17. 17FDA Briefing Document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. sections II.D.1.b and II.D.2.a
  18. 18FDA Briefing Document: TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. sections II.D.1.b and II.D.2

This guide explains what labels and published studies say. It isn't medical advice and doesn't replace your prescriber or pharmacist.

Spotted a mistake or something out of date? Tell us. We aim to fix factual errors within two working days.